Tanespimycin

Tanespimycin
Names
	IUPAC name [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-21-(allylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate
	Other names 17-N-Allylamino-17-demethoxygeldanamycin; 17-AAG
Identifiers
CAS Number	75747-14-7 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEMBL	ChEMBL109480 ;
ChemSpider	21106220 ;
IUPHAR/BPS	7751;
PubChem CID	6440175;
UNII	4GY0AVT3L4 ;
CompTox Dashboard (EPA)	DTXSID5046352 ;
	InChI InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1 Key: AYUNIORJHRXIBJ-TXHRRWQRSA-N ; InChI=1/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1 Key: AYUNIORJHRXIBJ-TXHRRWQRBY;
	SMILES NC(=O)O[C@H]1C(/C)=C/[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)C\C2=C(/NCC=C)C(=O)\C=C(\NC(=O)C(\C)=C\C=C/[C@@H]1OC)C2=O; C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\C)C)O)OC;
Properties
Chemical formula	C31H43N3O8
Molar mass	585.698 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin, 17-AAG) is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors.

It works by inhibiting Hsp90, which is expressed in those tumors.^[1]

It belongs to the family of drugs called antitumor antibiotics.

Clinical trials

Bristol-Myers Squibb conducted Phase 1^[2]^[3] and Phase 2 clinical trials. However, in 2010 the company halted development of tanespimycin, during late-stage clinical trials as a potential treatment for multiple myeloma. While no definitive explanation was given, it has been suggested that Bristol-Myers Squibb halted development over concerns of the financial feasibility of tanespimycin development given the 2014 expiry of the patent on this compound, and the relative expense of manufacture.^[4]

References

^ Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG (February 2011). "Tanespimycin as antitumor therapy". Clinical Lymphoma, Myeloma & Leukemia. 11 (1): 17–22. doi:10.3816/CLML.2011.n.002. PMID 21454186.
^ Clinical trial number NCT00093821 for "Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors" at ClinicalTrials.gov
^ Clinical trial number NCT00079404 for "Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia" at ClinicalTrials.gov
^ "Bristol-Myers Squibb Halts Development of Tanespimycin". The Myeloma Beacon. 22 July 2010. Archived from the original on 28 December 2010.

External links

[1] Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG (February 2011). "Tanespimycin as antitumor therapy". Clinical Lymphoma, Myeloma & Leukemia. 11 (1): 17–22. doi:10.3816/CLML.2011.n.002. PMID 21454186.

[2] Clinical trial number NCT00093821 for "Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors" at ClinicalTrials.gov

[3] Clinical trial number NCT00079404 for "Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia" at ClinicalTrials.gov

[available-4] "Bristol-Myers Squibb Halts Development of Tanespimycin". The Myeloma Beacon. 22 July 2010. Archived from the original on 28 December 2010.

[1]

[2]

[3]

[4]